Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (7781)	1/21/2003 5:41:38 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

Speaking of the dangers of combining floorless convertibles with biotechs that change their names: Message 18471444 I'd lost track of them after their name-change from Microcide. It's amazing to see that they now intend to issue 80 million new common shares (on top of the 18 million now outstanding) to get rid of their converts. Looks like the existing common holders are balking at doing this, although the alternative is almost certainly worse. Peter

To: Biomaven who wrote (7781)	1/21/2003 11:00:03 PM
From: Jibacoa	Read Replies (1) \| Respond to of 52153

<<Looks like good results for ALT.>> Yes, It seems it should help it to get over its November 1st H, although the market appears now inclined to disregard good news. BSX also announced pretty good news today. It has doubled since its low in January last year in spite of the general market and has had a good % gain since my previous comments on this thread on the results of its TAXUS II trial. Message 18472868 Bernard